O	0	2	No
O	3	11	Evidence
O	12	15	for
O	16	22	Effect
O	23	25	of
B-intervention	26	34	Exercise
O	35	37	on
O	38	51	Transcriptome
O	52	54	of
O	55	57	NK
O	58	63	Cells
O	64	66	in
O	67	73	Breast
O	74	80	Cancer
O	81	89	Patients
O	90	100	Undergoing
O	101	109	Adjuvant
O	110	117	Therapy
O	117	118	:
O	119	126	Results
O	127	131	From
O	132	133	a
O	134	139	Pilot
O	140	145	Study
O	145	146	.

O	147	159	Mobilization
O	160	163	and
O	164	174	activation
O	175	177	of
O	178	185	natural
O	186	192	killer
O	193	198	cells
O	199	200	(
O	200	202	NK
O	203	208	cells
O	208	209	)
O	210	214	have
O	215	219	been
O	220	232	hypothesized
O	233	235	to
O	236	246	contribute
O	247	249	to
O	250	258	observed
O	259	269	protective
O	270	277	effects
O	278	280	of
O	281	289	exercise
O	290	292	on
O	293	299	cancer
O	300	311	development
O	312	315	and
O	316	327	progression
O	327	328	.

O	329	333	Some
O	334	342	evidence
O	343	349	exists
O	350	353	for
O	354	359	acute
O	360	367	effects
O	368	370	of
O	371	378	aerobic
O	379	387	exercise
O	388	390	on
O	391	393	NK
O	394	398	cell
O	399	411	mobilization
O	412	415	and
O	416	424	function
O	424	425	,
O	426	427	i
O	427	428	.
O	428	429	e
O	429	430	.
O	430	431	,
O	432	442	alteration
O	443	445	of
O	446	449	the
O	450	454	gene
O	455	465	expression
O	466	473	profile
O	474	476	of
O	477	479	NK
O	480	485	cells
O	485	486	.

O	487	490	Yet
O	490	491	,
O	492	495	the
O	496	503	chronic
O	504	511	effects
O	512	514	of
O	515	523	exercise
O	524	532	training
O	532	533	,
O	534	537	and
O	538	545	effects
O	546	548	of
O	549	554	other
O	555	565	modalities
O	566	570	than
O	571	580	endurance
O	581	589	exercise
O	590	593	are
O	594	599	still
O	600	612	understudied
O	612	613	.

O	614	618	Here
O	618	619	,
O	620	622	we
O	623	635	investigated
O	636	639	the
O	640	647	chronic
O	648	655	effects
O	656	658	of
O	659	660	a
O	661	663	12
O	663	664	-
O	664	668	week
O	669	679	resistance
O	680	688	exercise
O	689	696	program
O	697	699	on
O	700	702	NK
O	703	707	cell
O	708	712	gene
O	713	723	expression
O	724	726	in
O	727	733	breast
O	734	740	cancer
O	741	749	patients
O	750	760	undergoing
O	761	769	adjuvant
O	770	775	chemo
O	775	776	-
O	777	779	or
O	780	792	radiotherapy
O	792	793	.

B-eligibility	794	800	Breast
I-eligibility	801	807	cancer
I-eligibility	808	816	patients
O	817	821	were
O	822	830	randomly
O	831	839	assigned
O	840	842	to
O	843	849	either
O	850	851	a
O	852	854	12
O	854	855	-
O	855	859	week
O	860	870	resistance
O	871	879	exercise
O	880	887	program
O	888	890	or
O	891	892	a
B-control	893	903	relaxation
I-control	904	911	control
I-control	912	917	group
O	918	929	concomitant
O	930	932	to
O	933	941	adjuvant
O	942	949	therapy
O	949	950	.

O	951	953	In
O	954	955	a
O	956	965	subsample
O	966	968	of
B-total-participants	969	971	19
O	972	984	participants
O	984	985	,
O	986	989	RNA
O	990	993	was
O	994	1003	extracted
O	1004	1008	from
O	1009	1015	magnet
O	1016	1020	bead
O	1021	1029	isolated
O	1030	1032	NK
O	1033	1038	cells
O	1039	1042	and
O	1043	1055	subsequently
O	1056	1064	analyzed
O	1065	1068	for
O	1069	1081	differential
O	1082	1086	gene
O	1087	1097	expression
O	1098	1103	using
O	1104	1114	microarray
O	1115	1123	Illumina
O	1124	1131	HumanHT
O	1131	1132	-
O	1132	1134	12
O	1135	1137	v4
O	1138	1144	before
O	1145	1148	and
O	1149	1154	after
O	1155	1158	the
O	1159	1171	intervention
O	1171	1172	.

O	1173	1178	After
O	1179	1186	chronic
O	1187	1195	exercise
O	1196	1208	intervention
O	1209	1216	several
O	1217	1222	genes
O	1223	1229	showed
B-outcome	1230	1236	higher
I-outcome	1237	1249	differential
I-outcome	1250	1260	expression
O	1261	1269	compared
O	1270	1272	to
O	1273	1276	the
O	1277	1284	control
O	1285	1290	group
O	1290	1291	.

O	1292	1299	However
O	1299	1300	,
O	1301	1306	after
O	1307	1317	correction
O	1318	1321	for
O	1322	1330	multiple
O	1331	1338	testing
O	1338	1339	,
O	1340	1348	baseline
O	1348	1349	-
O	1349	1357	adjusted
O	1358	1366	analyses
O	1367	1369	of
O	1370	1380	covariance
O	1381	1390	indicated
O	1391	1393	no
O	1394	1405	significant
O	1406	1417	differences
O	1418	1425	between
O	1426	1429	the
O	1430	1442	intervention
O	1443	1446	and
O	1447	1450	the
O	1451	1458	control
O	1459	1464	group
O	1465	1469	with
O	1470	1476	regard
O	1477	1479	to
O	1480	1483	the
B-outcome	1484	1488	gene
I-outcome	1489	1499	expression
I-outcome	1500	1507	profile
O	1507	1508	.

O	1509	1512	Our
O	1513	1521	findings
O	1522	1529	suggest
O	1530	1534	that
O	1535	1537	12
O	1537	1538	-
O	1538	1542	week
O	1543	1553	resistance
O	1553	1554	-
O	1554	1562	exercise
O	1563	1566	did
O	1567	1570	not
O	1571	1576	alter
O	1577	1580	the
O	1581	1585	gene
O	1586	1596	expression
O	1597	1604	profile
O	1605	1607	of
O	1608	1610	NK
O	1611	1616	cells
O	1617	1619	in
O	1620	1626	breast
O	1627	1633	cancer
O	1634	1642	patients
O	1643	1653	undergoing
O	1654	1662	adjuvant
O	1663	1670	therapy
O	1671	1673	on
O	1674	1677	the
O	1678	1682	long
O	1683	1687	term
O	1687	1688	.

O	1689	1696	Further
O	1697	1704	studies
O	1705	1709	with
O	1710	1716	larger
O	1717	1723	sample
O	1724	1729	sizes
O	1730	1733	and
O	1734	1746	specifically
O	1747	1755	designed
O	1756	1758	to
O	1759	1770	investigate
O	1771	1778	whether
O	1779	1787	exercise
O	1787	1788	-
O	1788	1795	induced
O	1796	1803	changes
O	1804	1806	in
O	1807	1809	NK
O	1810	1814	cell
O	1815	1823	function
O	1824	1827	are
O	1828	1838	attributed
O	1839	1841	to
O	1842	1847	acute
O	1848	1855	effects
O	1856	1859	are
O	1860	1869	warranted
O	1869	1870	.
